CL2008003232A1 - Compuestos derivados de bencensulfonanilida; composición farmacéutica que los comprende; y uso en el tratamiento de enfermedades del sistema nervioso central, disfunciones cognitivas, esquizofrenia, enfermedades adictivas, enfermedad de alzheimer u obesidad. - Google Patents
Compuestos derivados de bencensulfonanilida; composición farmacéutica que los comprende; y uso en el tratamiento de enfermedades del sistema nervioso central, disfunciones cognitivas, esquizofrenia, enfermedades adictivas, enfermedad de alzheimer u obesidad.Info
- Publication number
- CL2008003232A1 CL2008003232A1 CL2008003232A CL2008003232A CL2008003232A1 CL 2008003232 A1 CL2008003232 A1 CL 2008003232A1 CL 2008003232 A CL2008003232 A CL 2008003232A CL 2008003232 A CL2008003232 A CL 2008003232A CL 2008003232 A1 CL2008003232 A1 CL 2008003232A1
- Authority
- CL
- Chile
- Prior art keywords
- diseases
- benzenesulfonanilide
- obesity
- treatment
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Compuestos derivados de bencensulfonanilida; composición farmacéutica que los comprende; y uso en el tratamiento de enfermedades del sistema nervioso central, enfermedades adictivas u obesidad.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US165607P | 2007-11-02 | 2007-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008003232A1 true CL2008003232A1 (es) | 2009-11-27 |
Family
ID=40340548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008003232A CL2008003232A1 (es) | 2007-11-02 | 2008-10-29 | Compuestos derivados de bencensulfonanilida; composición farmacéutica que los comprende; y uso en el tratamiento de enfermedades del sistema nervioso central, disfunciones cognitivas, esquizofrenia, enfermedades adictivas, enfermedad de alzheimer u obesidad. |
Country Status (22)
Country | Link |
---|---|
US (2) | US7790727B2 (es) |
EP (1) | EP2217583B1 (es) |
JP (1) | JP2011502973A (es) |
KR (1) | KR20100100849A (es) |
CN (1) | CN101918384A (es) |
AR (1) | AR069151A1 (es) |
AT (1) | ATE535517T1 (es) |
AU (1) | AU2008320821A1 (es) |
BR (1) | BRPI0819233A2 (es) |
CA (1) | CA2704529A1 (es) |
CL (1) | CL2008003232A1 (es) |
ES (1) | ES2378596T3 (es) |
IL (1) | IL205469A0 (es) |
MX (1) | MX2010004832A (es) |
NZ (1) | NZ585087A (es) |
PA (1) | PA8802201A1 (es) |
PE (1) | PE20091016A1 (es) |
RU (1) | RU2010122300A (es) |
TW (1) | TW200927117A (es) |
UY (1) | UY31447A1 (es) |
WO (1) | WO2009056632A1 (es) |
ZA (1) | ZA201003594B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8802201A1 (es) * | 2007-11-02 | 2009-06-23 | Abbott Gmbh & Co Kg | Compuestos de bencensulfonalida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 |
CA2759491A1 (en) * | 2009-04-30 | 2010-11-04 | Abbott Gmbh & Co. Kg. | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
WO2015158313A1 (en) | 2014-04-19 | 2015-10-22 | Sunshine Lake Pharma Co., Ltd. | Sulfonamide derivatives and pharmaceutical applications thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
GB9818914D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
GB9818916D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
SE0002739D0 (sv) * | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New use |
US7381728B2 (en) * | 2004-07-28 | 2008-06-03 | Glaxo Group Limited | Piperazine derivatives useful for the treatment of gastrointestinal disorders |
PA8802201A1 (es) * | 2007-11-02 | 2009-06-23 | Abbott Gmbh & Co Kg | Compuestos de bencensulfonalida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 |
-
2008
- 2008-10-29 PA PA20088802201A patent/PA8802201A1/es unknown
- 2008-10-29 CL CL2008003232A patent/CL2008003232A1/es unknown
- 2008-10-30 PE PE2008001857A patent/PE20091016A1/es not_active Application Discontinuation
- 2008-10-31 MX MX2010004832A patent/MX2010004832A/es active IP Right Grant
- 2008-10-31 CA CA2704529A patent/CA2704529A1/en not_active Abandoned
- 2008-10-31 UY UY31447A patent/UY31447A1/es not_active Application Discontinuation
- 2008-10-31 US US12/262,455 patent/US7790727B2/en not_active Expired - Fee Related
- 2008-10-31 EP EP08845310A patent/EP2217583B1/en not_active Not-in-force
- 2008-10-31 AU AU2008320821A patent/AU2008320821A1/en not_active Abandoned
- 2008-10-31 CN CN2008801242091A patent/CN101918384A/zh active Pending
- 2008-10-31 KR KR1020107012151A patent/KR20100100849A/ko not_active Application Discontinuation
- 2008-10-31 JP JP2010531536A patent/JP2011502973A/ja active Pending
- 2008-10-31 BR BRPI0819233A patent/BRPI0819233A2/pt not_active IP Right Cessation
- 2008-10-31 WO PCT/EP2008/064811 patent/WO2009056632A1/en active Application Filing
- 2008-10-31 ES ES08845310T patent/ES2378596T3/es active Active
- 2008-10-31 AT AT08845310T patent/ATE535517T1/de active
- 2008-10-31 NZ NZ585087A patent/NZ585087A/en not_active IP Right Cessation
- 2008-10-31 TW TW097142281A patent/TW200927117A/zh unknown
- 2008-10-31 RU RU2010122300/04A patent/RU2010122300A/ru not_active Application Discontinuation
- 2008-10-31 AR ARP080104790A patent/AR069151A1/es not_active Application Discontinuation
-
2010
- 2010-04-29 IL IL205469A patent/IL205469A0/en unknown
- 2010-05-20 ZA ZA2010/03594A patent/ZA201003594B/en unknown
- 2010-08-05 US US12/851,466 patent/US20110086863A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2008320821A1 (en) | 2009-05-07 |
US20090131452A1 (en) | 2009-05-21 |
WO2009056632A1 (en) | 2009-05-07 |
EP2217583B1 (en) | 2011-11-30 |
MX2010004832A (es) | 2010-10-20 |
BRPI0819233A2 (pt) | 2017-05-02 |
ATE535517T1 (de) | 2011-12-15 |
UY31447A1 (es) | 2009-05-29 |
ES2378596T3 (es) | 2012-04-16 |
KR20100100849A (ko) | 2010-09-15 |
IL205469A0 (en) | 2010-12-30 |
RU2010122300A (ru) | 2011-12-10 |
PA8802201A1 (es) | 2009-06-23 |
US20110086863A1 (en) | 2011-04-14 |
PE20091016A1 (es) | 2009-08-15 |
CN101918384A (zh) | 2010-12-15 |
TW200927117A (en) | 2009-07-01 |
NZ585087A (en) | 2012-06-29 |
ZA201003594B (en) | 2011-02-23 |
JP2011502973A (ja) | 2011-01-27 |
EP2217583A1 (en) | 2010-08-18 |
AR069151A1 (es) | 2009-12-30 |
CA2704529A1 (en) | 2009-05-07 |
US7790727B2 (en) | 2010-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008003593A1 (es) | Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer | |
CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
BRPI0814529A2 (pt) | Derivados de 2-3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas alfa2c para o uso no tratamento de doenças do sistema nervoso periférico e central. | |
CL2008001932A1 (es) | Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer. | |
GT200900294A (es) | Compuestos amino-heterocíclicos | |
MX2008009947A (es) | Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos. | |
CL2009000380A1 (es) | Compuestos derivados de heterociclos, moduladores de beta-amiloide; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la enfermedad de alzheimer, angioplastia cerebral amiloide, demencia multiinfarto, sindrome de down, entre otras. | |
CL2008000434A1 (es) | Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros. | |
CL2011000043A1 (es) | Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central. | |
UY29796A1 (es) | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
CL2007002207A1 (es) | Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma. | |
CL2007003303A1 (es) | Molecula de enlace para la proteina lingo-1; polinucleotido que la codifica; vector y celula que lo comprenden; composicion farmaceutica que comprende la molecula de enlace; y su uso para el tratamiento de lesiones del sistema nervioso central. | |
UY31673A1 (es) | "derivados heterocíclicos de urea y métodos de uso de los mismos-211" | |
UY31405A1 (es) | "piperidino-dihidrotienopirimidas sustituidas" | |
BRPI1009252A2 (pt) | composto, pró-droga, composição farmacêutica, métodos para prevenir ou tratar doenças do sistema nervoso central, e mal de alzheimer, e, uso do composto ou de uma pró-droga do mesmo | |
PA8564001A1 (es) | Aza-arilpiperazinas | |
CL2008001025A1 (es) | Compuestos derivados de pirimido[5,4-d]pirimidina-2,4,6,8-tetraona; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastorno metabolico, dislipidemia y cancer. | |
CL2008002689A1 (es) | Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia. | |
CL2007000161A1 (es) | Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. | |
CL2008002864A1 (es) | Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros. | |
PA8720801A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento de la depresion | |
CL2009000119A1 (es) | Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer. | |
CL2008002162A1 (es) | Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras. | |
CL2008001820A1 (es) | Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer. | |
MX2010006204A (es) | Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. |